RxDoctor Payments Data

Krystle Ray, APRN

Family · Phoenix, AZNPI 1184185282

Payments from drug & device makers

$1,741in general payments, 2019–2025

Across 46 payments — averaging $37.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$758
  • AbbVie$361
  • Lilly USA, LLC$130
  • Pfizer$127
  • Otsuka America Pharmaceutical, Inc.$124
  • Exact Sciences$110
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$1,741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$758
AbbVie17$361
Lilly USA, LLC2$130
Pfizer5$127
Otsuka America Pharmaceutical, Inc.1$124
Exact Sciences5$110
Abbott2$37
Indivior Inc.2$32
Protega Pharmaceutials Inc1$32
GSK1$15
Novo Nordisk1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,741 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$13,023
Medicare patients
74
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide11$12,887
Incruse ElliptaUmeclidinium Bromide12$3,976
Albuterol Sulfate HfaAlbuterol Sulfate41$829
Omega-3 Acid Ethyl Esters12$824
Diclofenac Sodium18$686
Gabapentin36$443
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$351
Levothyroxine Sodium23$328
Metoprolol Succinate12$290
Atorvastatin Calcium32$282
Trazodone Hcl29$236
Omeprazole21$225
Azithromycin29$188
Tamsulosin Hcl12$186
Fluticasone Propionate11$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$130$12,88711 claims
GSKIncruse Ellipta$15$3,97612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →